MicroRNA-145 inhibits lung cancer cell metastasis

Ling,Dong‑Jin; Chen,Zhong‑Shu; Zhang,Yang‑De; Liao,Qian‑De; Feng,Jian‑Xiong; Zhang,Xue‑Yu; Shi,Tian‑Sheng

doi:10.3892/mmr.2014.3036

MicroRNA-145 inhibits lung cancer cell metastasis

Authors:
- Dong‑Jin Ling
- Zhong‑Shu Chen
- Yang‑De Zhang
- Qian‑De Liao
- Jian‑Xiong Feng
- Xue‑Yu Zhang
- Tian‑Sheng Shi
View Affiliations

Affiliations: Department of General Surgery, Ministry of Health Hepatobiliary and Enteric Surgery Center, Xiangya School of Medicine, Central South University, Changsha, Hunan 410008, P.R. China, Department of Orthopaedics, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China, Department of Thoracic Surgery, Jiangxi Provincial Chest Hospital, Nanchang, Jiangxi 330006, P.R. China
Published online on: December 3, 2014 https://doi.org/10.3892/mmr.2014.3036
Pages: 3108-3114

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have identified a variety of microRNAs (miRNAs) that have important roles in cancer progression, particularly in tumor invasion and metastasis. Downregulation of miR‑145 was reported to occur in various types of human cancer; however, the role of miR‑145 in lung cancer metastasis and its potential mechanisms of action remain to be elucidated. The present study aimed to investigate the effects of miR‑145 on metastasis and epithelial‑mesenchymal transition (EMT) in A549 human lung adenocarcinoma cells. In addition, the underlying mechanisms by which miR‑145 regulates EMT were examined. The miR‑145 mimic was transfected into A549 cells; cell invasion and adhesion assays were then performed in order to investigate cell metastasis, and western blot analysis was used to examine the expression of EMT markers. In order to further examine the underlying mechanisms by which miR‑145 regulates EMT, a luciferase reporter assay was performed to determine whether miR‑145 targeted Oct4. In addition, the expression of Wnt3a and β‑catenin in A549 cells was measured following transfection with small hairpin RNA‑Oct4. To the best of our knowledge, the results of the present study demonstrated for the first time, that miR‑145 inhibited lung cancer cell metastasis and EMT via targeting the Oct4 mediated Wnt/β‑catenin signaling pathway.

View Figures

View References

1	Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Nguyen DX, Bos PD and Massagué J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
3	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
4	Bates RC and Mercurio AM: The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther. 4:365–370. 2005. View Article : Google Scholar : PubMed/NCBI
5	Brabletz T, Hlubek F, Spaderna S, et al: Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs. 179:56–65. 2005. View Article : Google Scholar : PubMed/NCBI
6	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
7	Bracken CP, Gregory PA, Khew-Goodall Y and Goodall GJ: The role of microRNAs in metastasis and epithelial-mesenchymal transition. Cell Mol Life Sci. 66:1682–1699. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Humphreys DT, Westman BJ, Martin DI and Preiss T: MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci USA. 102:16961–16966. 2005. View Article : Google Scholar : PubMed/NCBI
10	Nicoloso MS, Spizzo R, Shimizu M, et al: MicroRNAs - the micro steering wheel of tumour metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
11	Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
12	Sempere LF, Christensen M, Silahtaroglu A, et al: Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 67:11612–11620. 2007. View Article : Google Scholar : PubMed/NCBI
13	Schepeler T, Reinert JT, Ostenfeld MS, et al: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 68:6416–6424. 2008. View Article : Google Scholar : PubMed/NCBI
14	Sachdeva M and Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 70:378–387. 2010. View Article : Google Scholar :
15	Wang L, Tang H, Thayanithy V, et al: Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res. 69:9490–9497. 2009. View Article : Google Scholar : PubMed/NCBI
16	Arndt GM, Dossey L, Cullen LM, et al: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 9:3742009. View Article : Google Scholar : PubMed/NCBI
17	Yin R, Zhang S, Wu Y, et al: microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep. 25:1747–1754. 2011.PubMed/NCBI
18	Thiery JP, Acloque H, Huang RY, et al: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
19	Lim J and Thiery JP: Epithelial-mesenchymal transitions: insights from development. Development. 139:3471–3486. 2012. View Article : Google Scholar : PubMed/NCBI
20	Samavarchi-Tehrani P, Golipour A, David L, et al: Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell. 7:64–77. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhang J and Ma L: MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev. 31:653–662. 2012. View Article : Google Scholar : PubMed/NCBI
22	Scholer H, Ruppert S, Suzuki N, Chowdhury K and Gruss P: New type of POU domain in germ line-specific protein Oct4. Nature. 344:435–439. 1990. View Article : Google Scholar
23	Nichols J, Zevnik B, Anastassiadis K, et al: Formation of pluripotent stemcells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 95:379–391. 1998. View Article : Google Scholar : PubMed/NCBI
24	de Jong J and Looijenga LH: Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: history and future. Crit Rev Oncog. 12:171–203. 2006. View Article : Google Scholar
25	Kim RJ and Nam JS: OCT4 expression enhances features of cancer stem cells in a mouse model of breast cancer. Lab Anim Res. 27:147–152. 2011. View Article : Google Scholar : PubMed/NCBI
26	Zhang Y, Zhang X, Wang X, et al: Inhibition of LDH-A by lentivirus-mediated small interfering RNA suppresses intestinal-type gastric cancer tumorigenicity through the downregulation of Oct4. Cancer Lett. 321:45–54. 2012. View Article : Google Scholar : PubMed/NCBI
27	Chen Z, Xu WR, Qian H, et al: Oct4, a novel marker for human gastric cancer. J Surg Oncol. 99:414–419. 2009. View Article : Google Scholar : PubMed/NCBI
28	Guo Y, Liu S, Wang P, et al: Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology. 59:763–775. 2011. View Article : Google Scholar : PubMed/NCBI
29	Iida H, Suzuki M, Goitsuka R and Ueno H: Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol. 40:71–79. 2012.
30	Chien AJ, Conrad WH and Moon RT: A Wnt survival guide: from flies to human disease. J Invest Dermatol. 129:1614–1627. 2009. View Article : Google Scholar : PubMed/NCBI
31	Chien AJ and Moon RT: WNTS and WNT receptors as therapeutic tools and targets in human disease processes. Front Biosci. 12:448–457. 2007. View Article : Google Scholar
32	Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 5:691–701. 2004. View Article : Google Scholar : PubMed/NCBI
33	Fu Y, Zheng S, An N, et al: β-catenin as a potential key target for tumor suppression. Int J Cancer. 129:1541–1551. 2011. View Article : Google Scholar : PubMed/NCBI
34	Valenta T, Hausmann G and Basler K: The many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012. View Article : Google Scholar : PubMed/NCBI
35	Anson M, Crain-Denoyelle AM, Baud V, et al: Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest. 122:586–599. 2012. View Article : Google Scholar : PubMed/NCBI
36	Davidson KC, Adams AM, Goodson JM, et al: Wnt/β-catenin signaling promotes differentiation, not self-renewal, of human embryonic stem cells and is repressed by Oct4. Proc Natl Acad Sci USA. 109:4485–4490. 2012. View Article : Google Scholar